Dr. Michael Dudley co-leads the Infectious Disease Care Global Innovation Group, and is Head of Health Science Research and Development in infectious disease at The Medicines Company (and Rempex Pharmaceuticals, a wholly-owned subsidiary). He has over 30 years of experience in the discovery, preclinical and clinical development of antiinfectives. Prior to joining The Medicines Company (from acquisition of Rempex), he was a co-founder of Rempex Pharmaceuticals where he served as Chief Scientific Officer. Prior to Rempex, he held positions of increasing responsibilities at Mpex Pharmaceuticals, Diversa Corp and Essential Therapeutics/Microcide Pharmaceuticals. Prior to his career in industry, he held full-time appointments as professor and chairman at the University of Rhode Island College of Pharmacy (URI), and Brown University School of Medicine and was based at Roger Williams Medical Center in Providence, RI. Dr. Dudley has served as a consultant on several government advisory boards, notably CDCs Antimicrobial Resistance Working Group, and was an Editor for Antimicrobial Agents and Chemotherapy. He completed undergraduate work at Pepperdine University and his Doctor of Pharmacy (PharmD) from the University of California San Francisco (UCSF) in 1980, completed at residency at UCSF, and a fellowship in infectious diseases at Hartford Hospital.
Dr. Dudley will be speaking at World Anti-Microbial Resistance Congress USA 2016 about ‘Late stage development: A phase III development program for the treatment of Carbapanem-Resistant Enterobacteriacae’. This session will cover leading the fight against carbapanem-resistant Enterobacteriacae (CRE) in a landscape of limited treatment options, Phase 3 study design to treat gram negative organisms non-susceptible to antibiotics, and preliminary results and considerations for the future. To hear from Dr. Michael Dudley and other industry experts, attend World Anti-Microbial Resistance Congress USA 2016, held September 8-9 in Washington, DC.